Mattek Corporation

Mattek Corporation, a for-profit manufacturer of reconstructed human and animal tissue models and culture media headquartered in Ashland, Massachusetts, operates as a prime contractor (96% of recent awards) supplying specialized microtissue samples and assay kits to federal research agencies with no set-aside designations across full-and-open competitive procurements. Mattek is a foreign-owned subsidiary of Sartorius Corporation.

Mattek's concrete capability centers on manufacturing engineered 3D human tissue models—including respiratory epithelium, intestinal tissue, skin (pigmented and non-pigmented), lung, and nasal models—alongside non-human primate lung tissues and associated culture media and maintenance formulations. The source data spans 112 federal awards since 1987, with recent representative work including a $949 thousand purchase order from the National Center for Advancing Translational Sciences (NCATS) for 600 EpiAirway and 600 EpiAlveolar non-human primate microtissues to support SARS-CoV-2 variant and therapeutics testing (awarded March 2022); a $420 thousand order from NCATS for respiratory, skin, and intestinal human tissue models (July 2023); a $248 thousand CDC order for human lung tissue matrix samples to characterize SARS-CoV-2 variants (August 2023); and a $81 thousand FDA order for reconstructed human small intestine and skin models with microtissue samples and culture media designated as a total small business set-aside (August 2026).

Customer concentration is heavily weighted to the Department of Health and Human Services ecosystem. The top five customers by award count account for 46% of awards, anchored by NIH (18 awards), followed by FDA (9 awards, $185 thousand combined potential value), NCATS (9 awards, $2.2 million combined potential value), EPA Office of Research and Development (8 awards, $309 thousand), and NIAID (7 awards, $111 thousand). By potential value, NCATS dominates with $2.2 million across 9 awards, followed by the Department of the Navy Bureau of Medicine and Surgery ($689 thousand across 6 awards) and CDC Pittsburgh ($576 thousand across 4 awards), accounting for 93% of combined potential value across all 112 awards. Two Indefinite Delivery Contracts (Navy N6264514D5029 and Air Force F3361587C2742) carry only two and one task orders respectively, indicating Mattek does not rely significantly on standing IDIQs; the majority of work flows through direct purchase orders.

Recent activity is modest—three awards in 2026, two in 2025, five in 2024—with combined potential value of $4.2 million across all awards and combined dollars obligated of $20.1 million, indicating substantial prior-year funding concentration. Only two awards face ultimate completion within the next twenty-four months (combined potential value $114 thousand), presenting minimal near-term recompete pressure. Mattek subcontracts to Battelle Memorial Institute on respiratory and intestinal tissue models supporting the National Institute of Environmental Health Sciences toxicology program (awards in February 2026 and July 2025) and to Signature Science LLC on forensic analysis work requiring EpiDermFT tissues (May 2024). Top NAICS categories are Biological Product Manufacturing (17 awards), Research and Development in Biotechnology (16 awards), and R&D in Physical, Engineering, and Life Sciences (15 awards); PSC codes center on Laboratory Equipment and Supplies (32 awards) and Drugs and Biologicals (10 awards).